Rasagiline - Second-Generation MAO-B Inhibitor for the Treatment of Parkinson's Disease, No Country

Print

Cross-section of the human brain showing the substantia nigra, the region affected by Parkinson's disease. (Source: ABPI)
 
Next»

Return to Profile




Home
New On This Site
Products & Services
Company A-Z
Industry Projects
White Papers
Jobs & Careers
Press Releases
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area

For every phase of your drug development